Dual targeting of FAK—an integrin-linked non-receptor tyrosine kinase—and c-MYC by VS-6063 and JQ1 inhibitors leads to cell cycle arrest and decreased cell survival in ovarian cancer cells in vitro (89). The gene discussed is MYC; the disease is ovarian cancer.